TWI888610B - 抗ｃｄ７９ｂ抗體藥物偶聯物、其製備方法及其醫藥用途 - Google Patents

抗ｃｄ７９ｂ抗體藥物偶聯物、其製備方法及其醫藥用途 Download PDF

Info

Publication number
TWI888610B
TWI888610B TW110127556A TW110127556A TWI888610B TW I888610 B TWI888610 B TW I888610B TW 110127556 A TW110127556 A TW 110127556A TW 110127556 A TW110127556 A TW 110127556A TW I888610 B TWI888610 B TW I888610B
Authority
TW
Taiwan
Prior art keywords
ligand
pharmaceutically acceptable
acceptable salt
solvate
drug conjugate
Prior art date
Application number
TW110127556A
Other languages
English (en)
Chinese (zh)
Other versions
TW202214306A (zh
Inventor
任文明
梁金棟
許建煙
黃建
楊昌永
廖成
Original Assignee
大陸商上海拓界生物醫藥科技有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 大陸商上海拓界生物醫藥科技有限公司 filed Critical 大陸商上海拓界生物醫藥科技有限公司
Publication of TW202214306A publication Critical patent/TW202214306A/zh
Application granted granted Critical
Publication of TWI888610B publication Critical patent/TWI888610B/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68037—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a camptothecin [CPT] or derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
TW110127556A 2020-07-27 2021-07-27 抗ｃｄ７９ｂ抗體藥物偶聯物、其製備方法及其醫藥用途 TWI888610B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN202010730899.8 2020-07-27
CN202010730899 2020-07-27
CN202010735910 2020-07-28
CN202010735910.X 2020-07-28

Publications (2)

Publication Number Publication Date
TW202214306A TW202214306A (zh) 2022-04-16
TWI888610B true TWI888610B (zh) 2025-07-01

Family

ID=80037618

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110127556A TWI888610B (zh) 2020-07-27 2021-07-27 抗ｃｄ７９ｂ抗體藥物偶聯物、其製備方法及其醫藥用途

Country Status (11)

Country Link
US (1) US12642862B2 (enExample)
EP (1) EP4190812A4 (enExample)
JP (1) JP7817236B2 (enExample)
KR (1) KR20230044275A (enExample)
CN (1) CN115698079A (enExample)
AU (1) AU2021317378A1 (enExample)
BR (1) BR112023001359A2 (enExample)
CA (1) CA3184724A1 (enExample)
MX (1) MX2023001163A (enExample)
TW (1) TWI888610B (enExample)
WO (1) WO2022022508A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7821733B2 (ja) * 2020-01-22 2026-02-27 上海森輝医薬有限公司 エリブリン誘導体の薬物複合体、その調製方法及びその医薬的応用
MX2024000893A (es) * 2021-07-22 2024-02-06 Shanghai Senhui Medicine Co Ltd Farmaco conjugado de un derivado de eribulina.
EP4393514A1 (en) * 2021-08-24 2024-07-03 Kunshan Xinyunda Biotech Co., Ltd. Antibody-drug conjugate conjugated via breakable linker
IL311324A (en) * 2021-09-16 2024-05-01 Chia Tai Tianqing Pharmaceutical Group Co Ltd A drug-antibody conjugate against HER3, a preparation including it and its use
JP7767613B2 (ja) 2021-11-15 2025-11-11 システィミューン，インコーポレイテッド 二重特異性抗体－カンプトテシン薬物複合体及びその製薬的使用
CA3248952A1 (en) * 2022-01-26 2025-07-10 Shanghai Mabgen Biotech Ltd. PHARMACEUTICAL COMPOSITION COMPRISING AN ANTI-CD79B ANTIBODY-DRUG CONJUGATE AND ITS USE
EP4480499A1 (en) * 2022-02-16 2024-12-25 Medilink Therapeutics (Suzhou) Co., Ltd. Conjugate of antibody-eribulin or derivative thereof, intermediate thereof, preparation method therefor, pharmaceutical composition thereof and use thereof
KR20240150773A (ko) * 2022-02-24 2024-10-16 에보포인트 바이오사이언시스 컴퍼니 리미티드 항체 및 약물 접합체 및 이의 용도
CN119998325A (zh) * 2022-08-08 2025-05-13 Atb治疗公司 抗CD79b的人源化抗体
WO2024078612A1 (en) * 2022-10-14 2024-04-18 Genequantum Healthcare (Suzhou) Co., Ltd. Linker-payload compound, conjugates and applications thereof
CN117917248A (zh) * 2022-10-20 2024-04-23 英诺湖医药(杭州)有限公司 酶裂解连接子及包含其的配体-艾瑞布林偶联物
EP4623936A1 (en) * 2022-11-22 2025-10-01 Keymed Biosciences (Chengdu) Co., Ltd. Fused ring compound, conjugate thereof and use thereof
CN118271439B (zh) * 2022-12-29 2025-06-13 深圳泽安生物医药有限公司 抗CD79b抗体及其用途
KR20250143351A (ko) * 2023-04-12 2025-10-01 레메젠 코, 리미티드 모노메틸 아우리스타틴 e 화합물의 제조 및 정제 방법
WO2025162492A1 (zh) * 2024-01-29 2025-08-07 甘李药业股份有限公司 一种连接子、配体-药物偶联物及其医药用途
CN122514386A (zh) * 2024-02-02 2026-08-04 江苏恒瑞医药股份有限公司 抗CD79b抗体药物偶联物联合免疫治疗剂、化疗剂治疗肿瘤
WO2025209279A1 (zh) * 2024-04-03 2025-10-09 英诺湖医药(杭州)有限公司 一种抗b7h3抗体-艾瑞布林偶联物及其应用
WO2026006252A1 (en) * 2024-06-25 2026-01-02 Abbvie Inc. Anti-cd79b antibody drug conjugates

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111116745A (zh) * 2018-11-01 2020-05-08 上海新理念生物医药科技有限公司 抗CD79b抗体、其药物偶联物及其应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
GB9112536D0 (en) 1991-06-11 1991-07-31 Celltech Ltd Chemical compounds
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US20090068178A1 (en) 2002-05-08 2009-03-12 Genentech, Inc. Compositions and Methods for the Treatment of Tumor of Hematopoietic Origin
PT1644412E (pt) 2003-07-01 2015-12-23 Ucb Biopharma Sprl Fragmentos de anticorpos fab modificados
GB0315450D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
GB0315457D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
ES2605443T3 (es) 2003-11-06 2017-03-14 Seattle Genetics, Inc. Conjugados de auristatina con anticuerpos anti-HER2 o anti-CD22 y su uso en terapia
GB0411186D0 (en) 2004-05-19 2004-06-23 Celltech R&D Ltd Biological products
AU2016273960B2 (en) * 2007-07-16 2019-01-24 Genentech, Inc. Anti-CD79b antibodies and immunoconjugates and methods of use
PE20140625A1 (es) * 2007-07-16 2014-05-29 Genentech Inc ANTICUERPOS ANTI-CD79b E INMUNOCONJUGADOS HUMANIZADOS
EP2535350B1 (en) 2007-09-26 2018-01-24 UCB Biopharma SPRL Dual specificity antibody fusions
DK2657253T3 (en) * 2008-01-31 2017-10-09 Genentech Inc Anti-CD79b antibodies and immune conjugates and methods of use
US10407513B2 (en) 2008-09-26 2019-09-10 Ucb Biopharma Sprl Biological products
SI2992016T1 (en) 2013-05-02 2018-01-31 F. Hoffmann-La Roche Ag Combination therapy of an afucosylated cd20 antibody with a cd79b antibody-drug conjugate
CA2979671C (en) * 2014-09-23 2020-03-10 Genentech, Inc. Methods of using anti-cd79b immunoconjugates
MX386587B (es) 2014-12-05 2025-03-19 Genentech Inc ANTICUERPOS ANTI-CD79b Y MÉTODOS DE USO.
JP2019510000A (ja) 2016-02-26 2019-04-11 ジエンス ヘンルイ メデイシンカンパニー リミテッドＪｉａｎｇｓｕ Ｈｅｎｇｒｕｉ Ｍｅｄｉｃｉｎｅ Ｃｏ．，Ｌｔｄ． 新規トキシン及びその中間体の製造方法
JOP20190187A1 (ar) 2017-02-03 2019-08-01 Novartis Ag مترافقات عقار جسم مضاد لـ ccr7
CR20250325A (es) * 2018-04-13 2025-08-29 Genentech Inc Formulaciones inmunoconjugadas anti-cd79b estables (divisional expediente 2020-0550)
UA130338C2 (uk) 2018-09-26 2026-01-28 Джянгсу Хенгруй Медісін Ко., Лтд. Кон'югат ліганд-лікарський засіб аналога ексатекану, спосіб його отримання та його застосування
JP7408646B2 (ja) 2018-09-30 2024-01-05 ジエンス ハンソー ファーマスーティカル グループ カンパニー リミテッド 抗－ｂ７ｈ３抗体－エキサテカンアナログコンジュゲート及びその医薬用途
CA3127556A1 (en) * 2019-01-28 2020-08-06 Tuojie Biotech (Shanghai) Co., Ltd. Anti-cd79b antibody, antigen-binding fragment thereof, and pharmaceutical use thereof
JP7821733B2 (ja) * 2020-01-22 2026-02-27 上海森輝医薬有限公司 エリブリン誘導体の薬物複合体、その調製方法及びその医薬的応用

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111116745A (zh) * 2018-11-01 2020-05-08 上海新理念生物医药科技有限公司 抗CD79b抗体、其药物偶联物及其应用

Also Published As

Publication number Publication date
CA3184724A1 (en) 2022-02-03
WO2022022508A1 (zh) 2022-02-03
KR20230044275A (ko) 2023-04-03
US20230405138A1 (en) 2023-12-21
TW202214306A (zh) 2022-04-16
AU2021317378A1 (en) 2023-03-09
CN115698079A (zh) 2023-02-03
JP2023535598A (ja) 2023-08-18
EP4190812A4 (en) 2024-09-04
JP7817236B2 (ja) 2026-02-18
EP4190812A1 (en) 2023-06-07
US12642862B2 (en) 2026-06-02
MX2023001163A (es) 2023-02-22
BR112023001359A2 (pt) 2023-02-14

Similar Documents

Publication Publication Date Title
JP7817236B2 (ja) 抗ｃｄ７９ｂ抗体薬物複合体、その調製方法及びその医薬用途
JP7408646B2 (ja) 抗－ｂ７ｈ３抗体－エキサテカンアナログコンジュゲート及びその医薬用途
JP7720305B2 (ja) 抗クローディン抗体薬物複合体及びその医薬用途
TWI891749B (zh) 抗體-藥物偶聯物及其醫藥用途
WO2021190586A1 (zh) B7h3抗体-依喜替康类似物偶联物及其医药用途
TWI887316B (zh) 抗ｃｅａ抗體-依喜替康類似物偶聯物及其醫藥用途
KR20220130717A (ko) 항-trop-2 항체-엑사테칸 유사체 접합체 및 이의 의학적 용도
TWI888517B (zh) 抗ｐｓｍａ抗體-依喜替康類似物偶聯物及其醫藥用途
CN117460540A (zh) 艾日布林衍生物的药物偶联物
TW202519269A (zh) 靶向ｃ－Ｍｅｔ的抗體－藥物偶聯物及其醫藥用途
WO2023046003A1 (zh) 抗体药物偶联物及其制备方法和医药用途
RU2852363C1 (ru) Конъюгат антитела к cd79b и лекарственного средства, способ его получения и его фармацевтическое применение
RU2833323C1 (ru) Конъюгат антитела против cea и аналога эксатекана и его фармацевтическое применение
RU2826119C1 (ru) Коньюгат антитела к клаудину и лекарственного средства и его фармацевтическое применение
RU2830167C1 (ru) Конъюгат антитела к trop-2 и аналога экзатекана и его медицинское применение
HK40082496B (en) Anti-psma antibody-exatecan analogue conjugate and medical use thereof
HK40075050B (en) Anti-claudin antibody-drug conjugate and pharmaceutical use thereof
HK40082076B (en) Antibody-drug conjugate and medical use thereof
HK40074739B (en) Anti-cea antibody-exatecan analog conjugate and pharmaceutical use thereof